期刊文献+

慢性缺血性心力衰竭时心肌基质金属蛋白含量的变化 被引量:10

MMP_2 activity increase in an ovine model of chronic ischaemic heart failure
原文传递
导出
摘要 目的 :验证慢性缺血性心力衰竭时左心室扩张和重构与心肌基质金属蛋白酶 (MMPs)活性改变有关的假说。方法 :用重复多次冠状动脉内微球栓塞法对 11只羊造成中等程度慢性心力衰竭。在栓塞前和栓塞 6个月后用超声心动图测定心脏腔径及室壁厚度 ,用Mikro Millar压力传感导管测定左心室舒张末期压(LVEDP) ,左心室压力最大上升速率 (dP/dtmax) ,最大下降速率 (dP/dtmin) ,用左心室造影测定左心室射血分数(LVEF)。测定完上述参数后处死动物检测心脏MMPs活性并与 10只正常羊比较。用以明胶为底物的酶图法测定MMPs活性。结果 :与基础值相比 ,多次微球冠状动脉栓塞后 6个月 ,左心室舒张末期内径〔从 (4.0 0± 0 .4 1)~ (5 .30± 0 .36 )cm〕、左心室腔径 /室壁厚度比值〔从 (2 .30± 0 .31)~ (3.90± 0 .6 1)〕、左室舒张末期容积〔从(6 9.0 0± 17.5 4 )~ (12 3.2 0± 32 .5 5 )ml〕、LVEDP〔从 (7.80± 2 .6 1)~ (12 .90± 2 .15 )mmHg(1mmHg =0 .133kPa)〕均明显增高 (P <0 .0 1) ,而LVEF〔从 (5 6 .2 0± 8.2 9) %~ (33.80± 5 .88) % ,P <0 .0 1〕 ,LVdP/dtmax〔从(12 5 8± 2 32 )~ (988± 198)mmHg/s,P <0 .0 5〕 ,LVdP/dtmin〔从 (16 14± 4 97)~ (12 16± 2 79)mmHg/s,P <0 .0 5〕均明显下降。与? Objective:The aim of this study was to test the hypothesis that the LV dilation and remodelling during the development of CHF is associated with the change of Matrix metalloproteinases (MMPs) zymographic activity.Methods:Eleven sheeps were developed into moderate chronic heart failure by sequential microembolisation and the hearts were studied for MMPs after echocardiographic and hemodynamic evaluation 6 months after the development of CHF and compared with 10 normal sheeps. MMPs activity was determined by gelatin zymography.Results:Compared with the baseline data, left ventricular(LV) end diastolic diameter 〔from( 4.00 ± 0.41 )~( 5.30 ± 0.36 )cm〕, the ratio of LV diameter and wall thickness 〔from( 2.30 ± 0.31 )~( 3.90 ± 0.61 )〕, LV end diastolic volume 〔from( 69.00 ± 17.54 )~( 123.20 ± 32.55 )ml〕, LV end diastolic pressure〔from( 7.80 ± 2.61 )~( 12.90 ± 2.15 )mmHg〕 increased significantly 6 months after the development of CHF (P< 0.01 ). While the LV ejection fraction 〔from( 56.20 ± 8.29 )%~( 33.80 ± 5.88 )%, P< 0.001 〕, LV dP/dt max 〔from(1258±232)~(988±198)mmHg, P< 0.05 〕 and LVdP/dt min 〔from(1614±497)~(1216±279)mmHg, P< 0.05 〕 decreased significantly. Three and half fold increase in LV myocardial MMP 2 zymographic activity against the substrate gelatin was observed in CHF sheep as compared with the normal sheep. There were no significant difference in MMP 1 and MMP 9 zymographic activity between the two groups.Conclusion:Increase in LV myocardial MMP 2 zymographic activity has been found in CHF sheep and may be partly responsible for the LV dilation and remodelling seen in this model of heart failure.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2003年第1期26-29,共4页 Journal of Clinical Cardiology
关键词 心力衰竭 缺血性心肌病 基质金属蛋白酶 Heart failure Metrix metalloproteinase Ischemic cardiomyopathy Matrix metalloproteinases
  • 相关文献

参考文献14

  • 1[1]Cleutjens J P M. The role of matrix metalloproteinases in heart failure. Cardivas Res, 1996,32:816-821.
  • 2[2]Cleutjens J P M, Kandala J C, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol, 1995, 27: 1281-1292.
  • 3[3]Spinale F G, Coker M L, Thomas C V, et al. Time-dependent changes in matrix metalloproteinase activity during the progression of congestive heart failure. Relative to ventricular and myocyte function. Cir Res, 1998,82:482-495.
  • 4[4]Thomas C V, Coker M L, Zellner J L, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1998,97:1708-1715.
  • 5[5]Huang Y F, Kawaguchi O, Zeng B, et al. A stable ovine congestive heart failure model. A suitable substrate for left ventricular assist device assessment. ASAIO J, 1997,43:M408-413.
  • 6[6]Mann D L, Spinalae F G. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that bands. Circulation, 1998,98:1699-1702.
  • 7[7]Coker M L, Thomas C V, Clair M J, et al. Myocardial matrix metallotroteinases activity and aboundance with congestive heart failure. Am J Pathol, 1998,274(5 Pt 2): H1516-1523.
  • 8[8]Gilbert S J, Wotton P R, Tarlton J F, et al. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res, 1997,34:377-383.
  • 9[9]Tyagi S I,Kumar S G, Haas S J, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol, 1996,28:1415-1428.
  • 10[10]Li YY, Feldman A M, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinase in the failing human heart. Circulation, 1998,98:1728-1734.

同被引文献103

引证文献10

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部